Skip to main content

Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics

Written by Customer Service on . Posted in Public Companies.

  • The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders Professors Einar Stefánsson, and Thorsteinn Loftsson.
  • OPTIREACH is behind Oculis’ lead candidate OCS-01, currently in Phase 3 development in patients with Diabetic Macular Edema (DME) and for the treatment of inflammation and pain following cataract surgery.
  • The revolutionary and proprietary OPTIREACH technology enables the formulation of topical eye drops to reach the back-of-the-eye at therapeutic concentration, as shown in the recent positive and robust clinical trial results from the DIAMOND program with OCS-01 in DME.
  • The award also recognizes the successful journey of Oculis internationally and in broadening its portfolio with other novel and promising drug candidates for eye diseases including OCS-02, a topical anti-TNF alpha for ocular inflammation and OCS-05, a neuroprotective candidate for neuro-ophthalmology diseases, both in clinical development.

ZUG, Switzerland and BOSTON, June 12, 2023 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced it has won the 2023 Knowledge Award from the Icelandic Association of Business and Economics.

Oculis has received the Knowledge Award this year for its research developing Oculis’ OPTIREACH solubilizing formulation technology, by Professors Stefánsson and Loftsson, Oculis’ co-founded, which took place in Oculis’ laboratory in Iceland. OPTIREACH was created to solve the limitations of conventional eye drops, including the limited solubility of drugs in eye drop formulations, quick removal by tear flow and inability to deliver drugs to the retina.

The technology is one of the proprietary platforms underpinning Oculis’ highly differentiated pipeline of innovative product candidates, including lead candidate OCS-01, a novel, high concentration, preservative-free, topical formulation of dexamethasone, currently in Phase 3 development in patients with diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery. The technology is also being leverage in other ongoing formulation projects.

The award also recognized Oculis’ successful journey internationally and in broadening its portfolio which includes two additional promising and clinical stage assets: OCS-02, a topical anti-TNF alpha for ocular inflammation and OCS-05, a neuroprotective candidate for neuro-ophthalmology diseases.

Riad Sherif, M.D., CEO of Oculis, said: “I’m delighted that Oculis has been recognized with the Icelandic Knowledge Award this year. I would also like to congratulate Thorsteinn and Einar for their vision, resilience and hard work. The OPTIREACH technology, is key to our efforts to develop novel treatments that can help prescribers to improve patients’ eyesight and enhance their quality of life. With OPTIREACH, we have the opportunity to develop eye drops that can reach the back of the eye at therapeutic concentrations, changing the ophthalmology treatment paradigm and reducing the need for more invasive treatments.”

The Association of Business and Economics graduates is an Icelandic association of university graduates in the field of business and economics. It also welcomes individuals who share an interest in these fields.

Its primary objective is to encourage ongoing education in business and economics, facilitate discussions on issues and research in the field, and to provide members with practical information on matters that can further advance their careers. Furthermore, the Association is a platform to foster connections and relationships among professionals in these sectors.

The Knowledge Day is an annual ceremony that celebrates achievements within a specific theme. During the event, companies that have demonstrated excellence in relation to the chosen subject are awarded for their success which includes the prestigious Knowledge Award.

All winners of the Knowledge Day Award can be viewed here. 

More information about the Icelandic Association of Business and Economics is available here.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop retinal candidate for diabetic macular edema (DME); OCS-02, a topical eye drop biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Contacts

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577

Media Relations
Consilium Strategic Communications
Amber Fennell, Tracy Cheung, David Daley
oculis@consilium-comms.com

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the use of proceeds and timing and consummation of the offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that are described in the Risk Factors sections of the final prospectus for such offering to be filed with the SEC, any of which could cause the events and circumstances discussed in such forward-looking statements to not occur on the terms described or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Oculis undertakes no obligation to update any such forward-looking statements after the date hereof, except as required by law.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.